Coherus BioSciences says it has “become very clear to us” since its major announcement last month that “there’s really significant pent-up demand in the market for an on-body system in the hands of a biosimilar company such as Udenyca (pegfilgrastim-cbqv),” as it confirmed plans for a 2022 submission of a prior approval supplement to the Udenyca pre-filled syringe formulation.
The California-based biotech has taken a step closer on its journey to challenging the supremacy of Amgen’s Onpro on-body injector device for Neulasta (pegfilgrastim) by announcing recently
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?